CTLA4 and melanoma: There are no prospective studies evaluating the response of KIT mutant melanomas to immunotherapy, with one retrospective study showing an ORR of 20% in patients who received anti-CTLA-4 agents and had KIT mutations in exons 2, 11, 13, and 17.